News Releases

Year

12 Nov '19

Cortexyme Announces Third Quarter 2019 Financial Results and Provides Business Update

— Lead investigational medicine COR388, a potentially transformative new paradigm for addressing Alzheimer’s disease, continues to advance in Phase 2/3 GAIN clinical trial — Following successful May 2019 initial public offering, Cortexyme is well capitalized and focused on high quality execution of

PDF Version

01 Nov '19

Cortexyme Announces Oral Presentation on COR388 at Clinical Trials on Alzheimer’s Disease 2019

- Presentation will detail impact of Cortexyme’s lead compound, COR388, on ApoE in Alzheimer’s Disease patients - CTAD attendees are also invited to educational session focused on Cortexyme’s new investigational approach to AD treatment SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov.

PDF Version

26 Sep '19

Cortexyme Announces European Screening Now Underway in the Phase 2/3 GAIN Trial

- International study is evaluating whether a new investigational medicine targeting P. gingivalis bacteria can slow or halt the progression of Alzheimer’s disease - GAIN Trial opened for U.S. enrollment in Q2 2019 and is expected to include approximately 90 sites globally SOUTH SAN

PDF Version

31 Jul '19

Cortexyme to Present at the Canaccord Genuity Growth Conference on August 7th

-- Presentation to be webcast on Cortexyme’s website SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 31, 2019-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and

PDF Version

17 Jul '19

Cortexyme’s Approach to Addressing a Key Underlying Cause of Alzheimer’s Detailed at Alzheimer’s Association International Conference 2019

-- Rationale and design of the GAIN trial discussed in AAIC news briefing earlier this morning -- In Phase 1b testing, COR388 was associated with reductions in markers of inflammation and pathological ApoE fragmentation SOUTH SAN FRANCISCO, Calif. & LOS ANGELES --(BUSINESS WIRE)--Jul.

PDF Version

10 Jul '19

Cortexyme Announces Upcoming Data Presentations at the Alzheimer’s Association International Conference 2019

- Company’s novel approach to addressing Alzheimer’s to be featured in two Developing Topics abstracts at AAIC SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 10, 2019-- Cortexyme, Inc. (Nasdaq: CRTX), today announced that its work to pioneer a novel disease-modifying therapeutic approach to

PDF Version

19 Jun '19

Cortexyme Expands Clinical Advisory Board With Key Clinical and Regulatory Experts

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 19, 2019-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases, today announced four

PDF Version

10 Jun '19

Cortexyme to Present at National Academies Forum on Tuesday, June 11, 2019

-- Event will be webcast, with Cortexyme presentation expected to start at 2:05 p.m. EDT tomorrow afternoon SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 10, 2019-- Cortexyme, Inc. (Nasdaq: CRTX) today announced that Casey Lynch , the company’s chief executive officer, chairman, and

PDF Version

13 May '19

Cortexyme, Inc. Announces Closing of Initial Public Offering and the Exercise of the Underwriters’ Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 13, 2019-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases, today announced the

PDF Version

08 May '19

Cortexyme, Inc. Announces Pricing of Initial Public Offering

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 8, 2019-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases, today announced that it

PDF Version

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 16